LONDON (ShareCast) - (Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Monday that it has signed a two-year collaboration agreement with Imperial College London.
The AIM-traded firm said that under the collaboration, Imperial College would provide "significant" intellectual input and guidance on a number of innovative peptide assets.

Those assets were being developed at ImmuPharma's research and development subsidiary, ImmuPharma Biotech, in Bordeaux, the company said.

"We are all extremely excited to be working with such a world leading academic institute," said chief operating officer Tim Franklin.

"This union will be invaluable in guiding and progressing our earlier stage product development portfolio, as well as enhancing our intellectual property base."

At 1301 GMT, shares in ImmuPharma were down 2.81% at 6.41p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE